Kathleen Laporte - Feb 14, 2024 Form 4/A Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Role
Director
Signature
/s/ Charles Carter, Attorney-in-Fact
Stock symbol
CERO
Transactions as of
Feb 14, 2024
Transactions value $
$50,000
Form type
4/A
Date filed
2/21/2024, 05:57 PM
Date Of Original Report
Feb 16, 2024
Previous filing
Feb 5, 2024
Next filing
Mar 27, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERO Series A Convertible Preferred Stock Award $50K +50 $1,000.00* 50 Feb 14, 2024 Common Stock 5K $10.00 By the Kathleen LaPorte Revocable Trust F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date.
F2 The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the "Kathleen Trust") and has sole voting and disposition power with respect to the shares owned by the Kathleen Trust.

Remarks:

This amendment to the Form 4 originally filed on February 16, 2024 is being filed solely to correct the ownership form and nature of indirect beneficial ownership reported in columns 10 and 11 of Table II, respectively.